We are a research group working at the interface of chemistry and biology to design probes and inhibitors to investigate the intricate workings of human proteins and cells, with a particular interest in epigenetics and dementia.
We form part of Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) and the Centre for Medicines Discovery (CMD) in the University of Oxford’s Nuffield Department of Medicine.
Did you know?
By 2040, Alzheimer’s Disease is predicted to overtake cancer as the second-leading cause of death in developed countries.
Read about the key research areas which drives us.
In Focus.
Publication. A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors
Aiken et al.
Expert Opinion on Therapeutic Patents
Apr, 2025
Multidisciplinary.
Learn more about the team behind our work.
